menu search

European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
Cholesterol Transport Mediator™ VAR 200 is in development to reduce renal cholesterol and lipid accumulation that damages the kidneys’ filtration system in patients with glomerular diseases, including diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndrome WESTON, Fla., June 06, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical […] The post European Patent Office to Grant ZyVersa Therapeutics’ Pa... Read More
Posted: Jun 6 2023, 13:07
Author Name: forextv
Views: 101945

Search within

Pages Search Results: